Member States availing of the use of the vaccines approved under Article 2 shall ensure that the conditions set out in paragraphs 2 to 6 are met.

The following vaccines against bovine brucellosis are hereby approved for immunisation of female bovine animals under the conditions set out in Article 3:

amending Decision 2001/296/EC as regards the list of approved laboratories for checking the effectiveness of vaccination against rabies in certain domestic carnivores

The prohibition contained in paragraph 1 shall not apply to vaccination campaigns carried out by the industry and approved by the competent authorities of the Member States.

all or some of the female bovine animals have been vaccinated at not more than six months old with live Buck 19 vaccine or other vaccines approved under the procedure laid down in Article 29;

Commission Decision 2001/296/EC of 29 March 2001 authorising laboratories to check the effectiveness of vaccination against rabies in certain domestic carnivores(4), as amended by Decision 2001/808/EC(5), established a list of approved laboratories in the Member States.

A newly developed vaccine offers additional advantages to those already approved and in particular does not interfere with the diagnostic procedures applied in the framework of eradication programmes in force in some Member States in accordance with Community legislation.

The vaccines shall only be used by an official veterinary or a veterinary specifically authorised by the competent authority within a brucellosis eradication programme submitted by a Member State and approved by the Commission pursuant to Article 24(7) of Decision 90/424/EEC.

In order that appropriate bio-safety conditions are guaranteed to protect animal health, the African swine fever virus, its genome and antigens and vaccines for research, diagnosis or manufacture shall be manipulated or used only in places, establishments or laboratories approved by the competent authority.

It is therefore appropriate to approve, subject to certain conditions, the use of live strain RB 51 and live strain Rev.1 vaccines within brucellosis eradication programmes approved pursuant to Council Decision 90/424/EEC of 26 June 1990 on expenditure in the veterinary field(3), as last amended by Decision 2001/572/EC(4), in order to take into account scientific developments and international standards.

have been vaccinated, using officially approved vaccines (6).

using an officially approved and tested inactivated vaccine;1

the vaccination plan shall have been approved before the starting of the vaccination operations in accordance with paragraph 3,

that the chicks have been vaccinated, using officially approved vaccines, against:

The vaccination shall only take place on susceptible birds in a zoo or an approved body, institute or centre.

Safety and potency testing of foot-and-mouth disease vaccine and bluetongue vaccine can only be carried out at laboratories being operated under approved biose-curity levels.

(4) Further experience suggests amending the approved vaccination programme in order to include possible vaccination of breeding poultry and to modify the vaccination schemes applied to different categories of poultry, in particular to layers.

The amendments requested by Italy to the vaccination programme approved by Decision 2002/975/EC concerning in particular:

(3) The vaccination programme was approved by Commission Decision 2002/975/EC fn, which laid down the rules concerning vaccination against avian influenza in an area described in the Annex.

To certify in case of dispatch to a Member State, which has an EC-approved non-vaccinating status tor Newcastle disease currently:

To certify in case of dispatch to a Member State, which has an EC-approved non-vaccinating status for Newcastle disease currently:

- the exact address and location of the zoos and approved bodies, institutes or centres where the vaccination is to be carried out,

That system requires checks performed by officially approved laboratories on the effectiveness of the vaccination by titration of antibodies.

The vaccination programme against avian influenza presented by Italy is hereby approved and shall be carried out in the area described in Annex I.

(b) which contains no ovine or caprine animals which have been vaccinated against brucellosis (B. mefitensis), save those vaccinated at least two years previously with Rev. 1 vaccine or any other vaccine approved under the procedure laid down in Article 15 of this Directive;

In accordance with the procedure referred to in Article 27(2), the emergency vaccination plan may be approved or amendments and additions may be requested before approval is given.

(3) In order to control the spread of infection with low pathogenic avian influenza virus the Commission has approved a vaccination programme by Commission Decision 2002/975/EC(6).

(b) all or some of the ovine or caprine animals have been vaccinated with Rev. 1 vaccine or any other vaccine approved under the procedure laid down in Article 15 of this Directive.

(16) Monitoring on vaccinated and unvaccinated poultry flocks shall be continued including the use of the serological test (iIFA-test) which had been approved by Commission Decision 2001/847/EC(7).

(i) have been regularly inspected and tested with negative results for avian influenza as laid down in the approved vaccination programme, with particular attention to be paid to the sentinel birds.

(3) the animal was vaccinated on ………………………( 5 ), against equine viral arteritis under official veterinary supervision with a vaccine approved by the competent authority, according to the following programmes for initial vaccination and has been re-vaccinated at regular intervals ( 3 ) ( 4 ).

(3) the animal was vaccinated on ……………………………..(5) against equine viral arteritis under official veterinary supervision with a vaccine approved by the competent authority, according to the following programmes for initial vaccination and has been re-vaccinated at regular intervals ( 3 ) ( 4 ).

Vaccinated animals shall not be traded or moved unless under official supervision between zoos or approved bodies, institutes or centres in the same Member State, or after specific authorisation, of another Member State.

Commission Decision 2001/296/EC of 29 March 2001 authorising laboratories to check the effectiveness of vaccination against rabies in certain domestic carnivores(4) established a list of approved laboratories in the Member States.

equidae vaccinated against equine viral arteritis under official supervision with a vaccine approved by the competent authority and which have reacted with a negative result at 1 in 4 to a serum neutralization test for that disease.

(6) During the previous avian influenza epidemic in Italy a vaccination programme was approved by the Commission in connection with intensive monitoring and certain provisions for intra-Community trade in live poultry and poultry products.

(b)u - they have been vaccinated within the prescribed period of not less than fifteen days and not more than twelve months7 against types A, O and C of foot-and-mouth disease virus using an officially, approved and tested inactivated vaccine3;

seropositive having been vaccinated in accordance with Annex B Chapter II of Council Directive 88/407/EEC and having given a negative result to a serum neutralization test or an Elisa carried out in the approved semen collection centre prior to vaccination fn,

(6) Commission Decision 2002/341/EC of 3 May 2002 amending Decision 2001/296/EC as regards the list of approved laboratories for checking the effectiveness of vaccination against rabies in certain domestic carnivores fn is to be incorporated into the Agreement.

(ii) they must have been vaccinated with Rev. 1 vaccine or any other vaccine approved in accordance with the procedure laid down in Article 15 of this Directive before the ere of seven months and not less than 15 days before entering the bolding of destination.

(a) have been vaccinated at least fifteen days and not more than four months before loading against types A, O and C of the foot-and-mouth disease virus using an inactivated virus vaccine approved and controlled by the competent authority of the exporting country;

(a) have been vaccinated not less than fifteen days and not more than four months before loading against types A, O and C of the foot-and-mouth disease virus, using an inactivated virus vaccine approved and controlled by the competent authority of the exporting country;

Commission Decision of 3 May 2002 amending Decision 2001/296/EC as regards the list of approved laboratories for checking the effectiveness of vaccination against rabies in certain domestic carnivores (Text with EEA relevance) (notified under document number C(2002) 1584)

Commission Decision of 14 November 2001 amending Decision 2001/296/EC as regards the list of approved laboratories for checking the effectiveness of vaccination against rabies in certain domestic carnivores (Text with EEA relevance) (notified under document number C(2001) 3478)

shall proceed, in the zone laid down in (c), with the systematic vaccination of all equidae using a vaccine authorized by the competent authority, and shall identify them by a clear, indelible mark applied by an approved method in accordance with the procedure laid down in Article 19. However, on the basis of the epizootiological, meteorological, geographical or climatological circumstances, the vaccination requirements may be waived by the competent authority.

the animal was vaccinated on............................ ( 5 ) against equine viral arteritis under official veterinary supervision with a vaccine approved by the competent authority, according to the following programmes for initial vaccination and has been revaccinated at regular intervals ( 3 ) ( 4 ).

In order that appropriate bio-safety conditions are guaranteed to protect animal health, the classical swine fever virus, its genome and antigens and vaccines for research, diagnosis or manufacture shall be manipulated or used only in places, establishments or laboratories approved by the competent authority.

Whereas, taking account of the report from the Commission to the Council on the risks of transmission of Newcastle disease and the requirements to be met by Newcastle disease vaccines, provision should be made for certain Member States or regions to be approved as Newcastle disease non-vaccinating, if appropriate;